Introduction
============

The pharmacoproteomics has been widely applied to various aspects of current pharmaceutical researches by discovering disease-related genes ([@B48]; [@B54]; [@B86]) or new drug targets ([@B43]; [@B58]), constructing pharmacology screening model ([@B27]), and revealing the drug mechanism of action ([@B85]; [@B93]), resistance ([@B53]), and toxicity ([@B65]; [@B72]). Recent findings uncover its potentials to fulfill the promise that the pharmacogenomics has not accomplished yet ([@B17]; [@B12]; [@B83]). As a newly emerging technique ([@B4]), the *sequential windowed acquisition of all theoretical fragment ion mass spectra* (SWATH-MS) has been reported to provide much more comprehensive detection and accurate quantitation of proteins compared to the traditional techniques used in pharmacoproteomic analyses ([@B97]; [@B66]; [@B1]; [@B38]; [@B4]), and it thus becomes one of the most popular techniques for target discovery ([@B41]; [@B78]; [@B4]), drug/lead quantification ([@B56]) and identification ([@B61]; [@B71]; [@B5]; [@B39]), construction of assay library for targeted proteomic analysis ([@B62]), and quantitative protein profiling ([@B35]) for recognizing drug-induced alterations ([@B56]; [@B79]).

However, due to the interdependent nature among multiple acquisition parameters (dwell time, duty cycle, precursor isolation window width, and mass range), the protein quantification based on SWATH-MS is reported to be limited in dynamic range ([@B4]) and in turn low in accuracy ([@B25]; [@B29]; [@B63]; [@B82]; [@B81]). The problems above can be even worse considering the innate complexity of clinical samples ([@B31]), small amount of proteins ([@B59]), and low abundance of drug-metabolizing enzymes ([@B31]). To cope with these problems, a variety of popular quantification tools, including *DIA-Umpire* ([@B59]), *OpenSWATH* ([@B57]), *Skyline* ([@B46]), *Spectronaut* ([@B9]), and *SWATH2.0* ([@B40]), and dozens of subsequent processing methods (transformation, normalization, and missing-value imputation) are developed to enhance the accuracy of SWATH-MS ([@B50]). Recent reports further reveal that SWATH-MS' accuracies depend heavily on the specific quantification tool/processing method used in a particular study ([@B50]), and the protein quantification can significantly benefit from comparative benchmarking of the performance of these tools and methods ([@B24]; [@B88]). Therefore, it is urgently needed to assess the performances of tools/methods for discovering the optimal one(s) for SWATH-MS based pharmacoproteomic studies.

The performance of various quantification tools has already been systematically evaluated by benchmark SWATH-MS data ([@B50]). Among those tools, only 2 (*OpenSWATH* and *Skyline*) are non-commercial ones, and the *OpenSWATH* ([@B57]) is of the most popular one used to quantify SWATH-MS based pharmacoproteomic data ([@B57]; [@B52]; [@B73]). So far, ≥4 transformation, ≥15 normalization, and ≥6 missing-value imputation algorithms ([@B26]; [@B42]; [@B51]; [@B77]; [@B65]; [@B70]) have been sequentially applied to process pharmacoproteomic data. Among these algorithms, four for normalizing label-free proteomic data have been assessed to identify the best performed one ([@B10]) and six for missing-value imputation have been evaluated to discover the one enhancing proteomic quantifications in the differential expression analysis ([@B68]). Appropriate integrations of the processing methods into a sequential analysis chain are reported to improve the quantification accuracies ([@B32]; [@B14]; [@B68]) with some chains identified as highly accurate in particular pharmacoproteomic studies ([@B26]; [@B51]; [@B65]; [@B89]). For example, log transformation followed by median normalization performs well in identifying the therapeutic target/pathway for *Down syndrome* ([@B64]), endogenous toxins inducing the haploinsufficiency of tumor suppressor ([@B65]) and biological mechanism underlying the role of proteins played in *Alzheimer's disease* ([@B33]). Since the processing methods are sequentially used to form the integrated analysis chain ([@B26]; [@B51]; [@B65]), any performance assessment aiming solely at transformation, normalization, or imputation may not be able to reflect the overall performance of the whole analysis chain. Considering the huge amount of possible analysis chains \[560 in total, taking non-transformation, non-normalization, and non-imputation into account adopted by previous studies ([@B26]; [@B45]; [@B77])\] by randomly integrating those processing methods, it is therefore essential to comprehensively evaluate the performance of all analysis chains to identify the optimal one for specific pharmacoproteomic dataset. However, no such analysis has been conducted yet.

In this study, the performances of all possible analysis chains integrating 4 transformation, 15 normalization, and 6 imputation algorithms were comprehensively assessed by their precisions based on the proteomes among replicates ([@B36]; [@B50]; [@B16]; [@B49]). Systematic literature review on the popular quantification tool *OpenSWATH* firstly yielded seven SWATH-MS based benchmark pharmacoproteomic datasets of varied sample sizes (from 6 to 116). To the best of our knowledge, these seven provided the most complete set of the publicly available pharmacoproteomic data based on the SWATH-MS technique. Secondly, the performance of analysis chains was assessed by each dataset. Thirdly, the analysis chains consistently performed well across all datasets were identified for the first time and compared with those popular chains frequently applied in current pharmacoproteomic studies. Finally, the consistently well-performed analysis chains were further discussed based on their performances. The analysis chains identified in and the corresponding findings of this study provided important guidance to current pharmacoproteomic studies.

Materials and Methods {#s1}
=====================

Collection of SWATH-MS Based Benchmark Pharmacoproteomic Datasets
-----------------------------------------------------------------

A systematic literature review on the popular quantification tool *OpenSWATH* and the analysis on the datasets provided in the PRIDE database ([@B50]) were collectively conducted to find SWATH-MS based benchmark pharmacoproteomic datasets. Firstly, PRIDE database was searched against by keyword "SWATH-MS." Together with the literature review on the resulting projects, 85 projects were identified as based on SWATH-MS, among which 76 and 9 projects were acquired by TripleTOF instruments 5600 and 6600, respectively. Secondly, several criteria were used to guarantee the availability and processability of the raw proteomic data, which included (1) complete set of raw data files, (2) well-defined parameters (isolation scheme, range of retention time, and transition settings), (3) availability of spectral library and protein database to search against, and (4) clear description on sample groups. The application of these criteria on the resulting PRIDE projects yielded seven SWATH-MS based benchmark pharmacoproteomic datasets of varied sample sizes (**Table [1](#T1){ref-type="table"}**), which covered both TripleTOF instruments (5600 and 6600) of all 85 projects. Therefore, these datasets can be recognized as representatives of SWATH-MS based pharmacoproteomic data. To the best of our knowledge, these datasets provided the most complete set of SWATH-MS based pharmacoproteomic data.

###### 

Seven SWATH-MS based benchmark pharmacoproteomic datasets collected for the analysis of this study.

  Datasets             PRIDE ID    Sample size and Dataset description                             Analysis Chain   Instrument
  -------------------- ----------- --------------------------------------------------------------- ---------------- ----------------
  *Nat. Biotechnol*.   PXD002952   3 samples of 65% human, 30% yeast, and 5% *E. coli* proteins    LOG-MED-???      TripleTOF 6600
  34:1130-6, 2016                  3 samples of 65% human, 15% yeast, and 20% *E. coli* proteins                    
  *Cell Rep*.          PXD003278   6 siRNA-treated Cal51 cell samples                              LOG-QUA-NON      TripleTOF 5600
  20:1229-41, 2017                 6 PRPF8-depleted Cal51 cell samples                                              
  *Cell*.              PXD006106   10 formaldehyde treated HeLa Kyoto cell samples                 LOG-MED-NON      TripleTOF 5600
  169:1105-18, 2017                10 formaldehyde untreated HeLa Kyoto cell samples                                
  *Nat Med*.           PXD000672   18 tumorous kidney tissue biopsies                              LOG-QUA-NON      TripleTOF 5600
  21:407-13, 2015                  18 non-tumorous kidney tissue biopsies                                           
  *Sci Rep*.           PXD004880   18 plasma samples from individuals with *Down syndrome*         LOG-MED-NON      TripleTOF 5600
  7:14818, 2017                    18 plasma samples from healthy controls                                          
  *Cell Rep*.          PXD003972   20 wild type mouse samples                                      LOG-???-???      TripleTOF 5600
  18:3219-26, 2017                 20 knock-in mouse samples expressing endogenous GRB2                             
  *Mol Syst. Biol*.    PXD001064   72 blood samples of monozygotic twins                           ???-RLR-BAK      TripleTOF 5600
  11:786, 2015                     44 blood samples of dizygotic twins                                              

All datasets were from PRIDE database (

Navarro et al., 2016

). Each method in the analysis chain was abbreviated by a three-letter code as demonstrated in Supplementary Table

S1

, and ??? indicated that the corresponding method was not specified in the corresponding study of the dataset.

Processing Methods for Data Transformation, Normalization, and Imputation
-------------------------------------------------------------------------

So far, ≥4 transformation, ≥15 normalization, and ≥6 missing-value imputation algorithms ([@B26]; [@B42]; [@B51]; [@B77]; [@B65]; [@B70]) have been reported to be sequentially and frequently used to process pharmacoproteomic data. Based on our comprehensive literature review, their corresponding applications to current proteomic research were discussed in Supplementary Method [S1](#SM1){ref-type="supplementary-material"}. These 25 methods include 4 ***transformation***: *Box-cox* ([@B60]), *Cube Root* ([@B74]), *Log* ([@B18]), and *Power* ([@B87]), 15 ***normalization***: *Auto Scaling* ([@B34]), *Cyclic Loess* ([@B96]), *EigenMS* ([@B91]), *Locally Weighted Scatterplot Smoothing* ([@B75]), *Mean* ([@B3]), *Median* ([@B7]), *Median Absolute Deviation* ([@B47]), *Pareto* ([@B90]), *Probabilistic Quotient* ([@B19]), *Quantile* ([@B10]), *Robust Linear Regression* ([@B28]), *Total Ion Current* ([@B23]), *Trimmed Mean of M Values* ([@B44]), *VSN* ([@B30]), and *Z-score* ([@B15]), and 6 ***imputation***: *Background* ([@B11]), *Bayesian Principal* ([@B11]), *Censored* ([@B68]), *K-nearest Neighbor* ([@B92]), *Singular Value Decomposition* ([@B2]), and *Zero Imputation* ([@B22]). As shown in the Supplementary Method [S1](#SM1){ref-type="supplementary-material"}, due to their popularity in current pharmacoproteomic studies, these 25 methods were included, sequentially applied, and analyzed in this study. Each method was abbreviated by a three-letter code which was demonstrated in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.

Assessing Analysis Chain Using the Precision Based on Proteomes Among Replicates
--------------------------------------------------------------------------------

Diverse methods for proteomic data processing (transformation, normalization, and imputation) profoundly affected the precision of protein quantification which was frequently assessed using the value of pooled intragroup median absolute deviation (PMAD) of reported protein intensity among replicates ([@B13]; [@B36]; [@B69]; [@B84]). Particularly, the PMAD was designed to demonstrate the capacity of each analysis chain to reduce the variation among replicates, and therefore to enhance the technical reproducibility ([@B13]). The lower value of PMAD denoted the more thorough removal of the experimentally induced noise and indicated better precision of the corresponding analysis chain ([@B69]). So far, PMAD value within the range of ≤0.3, \>0.3 & ≤0.7, and \>0.7 was generally accepted as with superior, good, and poor precision, respectively ([@B13]; [@B69]), which had gradually become a popular metric for assessing the precision of processing methods in OMICs ([@B13]; [@B69]).

Performance Assessment Among Various Analysis Chains by Hierarchical Clustering
-------------------------------------------------------------------------------

Pooled intragroup median absolute deviation values of 560 possible analysis chains across the seven benchmark datasets were firstly calculated. Fifty-one out of these 560 analysis chains reported error for processing at least one of the benchmark datasets. Therefore, the hierarchical clustering of the remaining 509 analysis chains with calculatable results of all seven PMADs was conducted to identify the relationship among the performances of various analysis chains. Particularly, PMAD values of a specific analysis chain among 7 datasets were used to form a 7-dimensional vector. Then, hierarchical clustering was applied to investigate the relationship among those 509 vectors, and therefore among the corresponding analysis chains. To measure the distance between any 2 vectors, the *Euclidean distance* was adopted, which could be demonstrated as below:
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where *i* denoted each dimension of the analysis chain *a* and *b*. The clustering algorithm applied here was Ward's minimum variance algorithm ([@B6]), which was designed to minimize the total within-cluster variance. Ward's minimum variance module in R package ([@B67]) was used. To visualize the hierarchical tree graph among those 509 analysis chains, the tree generator *iTOL* was used to generate and display the hierarchical tree structure ([@B37]).

Results and Discussion
======================

Ranking the Analysis Chains Based on Their Performances on Each Benchmark
-------------------------------------------------------------------------

The performances of each analysis chain on the seven SWATH-MS based benchmark datasets (**Table [1](#T1){ref-type="table"}**) were assessed by measuring the corresponding PMAD values. As shown in **Figure [1](#F1){ref-type="fig"}**, the performances of 509 analysis chains (log ~10~PMAD, *Y*-axis) with calculatable PMAD values were measured and ranked (*X*-axis). Because some analysis chains may not be able to result in a PMAD value, there were slight variations among the number of analysis chains for different benchmark datasets (from 530 to 560). Taking the dataset shown in the center of **Figure [1](#F1){ref-type="fig"}** as an example (Nat Med. 21:407-13, 2015), a total of 558 analysis chains were assessed and ranked, and the performance of different analysis chains varied significantly (PMAD from 1.8 × 10^-15^ to 2.0 × 10^5^). With reference to the frequently adopted cutoff (PMAD = 0.7) for differentiating the analysis chains of good and poor precision ([@B13]; [@B69]), 203 (36.4%) out of these 558 analysis chains were ranked as well-performed. Similar to this dataset (Nat Med. 21:407-13, 2015), the performance of different analysis chains for the other datasets also differentiated substantially (PMAD from 1.7 × 10^-16^ to 3.4 × 10^5^) with 38.8%∼49.7% of the analysis chains ranked as well-performed.

![The performances of each analysis chain on those seven SWATH-MS based benchmark datasets assessed by measuring the corresponding PMAD values \[\>500 analysis chains (log ~10~PMAD, *Y*-axis) were measured and ranked (*X*-axis)\]. Since some analysis chains may not be able to result in a specific PMAD value, there were slight variations among the number of analysis chains for different benchmark datasets (from 530 to 560). Detail information on these seven datasets were provided in **Table [1](#T1){ref-type="table"}**.](fphar-09-00681-g001){#F1}

The specific analysis chains for each benchmark dataset adopted in the corresponding original studies were identified by literature review (**Table [1](#T1){ref-type="table"}**). Particularly, 4 out of these datasets were with the clearly defined analysis chain (LOG-QUA-NON, LOG-MED-NON, LOG-QUA-NON, and LOG-MED-NON for PXD003278, PXD006106, PXD000672, and PXD004880, respectively), while the remaining 3 datasets were with incomplete information of the adopted analysis chain (LOG-MED-???, LOG-???-???, and ???-RLR-BAK for the datasets of PXD002952, PXD003972, and PXD001064, respectively). Taking the same dataset in the middle of **Figure [1](#F1){ref-type="fig"}** as an example (Nat Med. 21:407-13, 2015), the red dot indicated the PMAD of the analysis chain adopted by this study and its corresponding ranking among all 558 analysis chains. As shown, the adopted chain (LOG-QUA-NON) in this study was ranked to be the 156th well-performed one (PMAD = 0.598) showing its capacity to reduce variations among replicates and thus enhance technical reproducibility ([@B13]). However, there were 155 chains performed better than the adopted one (PMAD from 1.8 × 10^-15^ to 0.595) with POW-TMM-ZER chain performed the best. Similar to this example dataset, the analysis chains adopted by the corresponding studies of PXD003278, PXD006106, and PXD004880 were ranked 162nd, 154th, and 164th well-performed ones, which demonstrated appropriate selection of analysis chain in previous studies. However, there were still more than a hundred chains performed better than the adopted ones, which may further enhance the accuracy of SWATH-MS based protein quantification. For the studies with incomplete information of the adopted chain (PXD002952, PXD003972, and PXD001064), the possible integrations based on the known information were highlighted by multiple red dots. 1 (20%) out of 5, 28 (25%) out of 112, and 7 (100%) out of 7 integrations were within the ranges of well-performance for PXD002952, PXD003972, and PXD001064, respectively.

Analysis Chains Consistently Well-Preformed Across All Benchmark Datasets
-------------------------------------------------------------------------

The performances of 20 representative analysis chains across different datasets were illustrated in **Figure [2](#F2){ref-type="fig"}**. PMAD within the ranges of ≤0.3, \>0.3 & ≤0.7, and \>0.7 was generally accepted as with superior, good, and poor performance, respectively ([@B13]; [@B69]), which was illustrated by a circle of various diameters (the smaller diameter denoted the lower PMAD value). As shown, the performances of specific chain among various datasets varied significantly. Particularly, the LOG-PQN-BPC performed superior, good, and poor in 3, 3, and 1 datasets, respectively, and POW-ZSC-ZER performed superior, good, and poor in 1, 5, and 1 datasets, respectively. These results demonstrated a certain level of variations among the seven datasets for each analysis chain. However, as shown in **Figure [2](#F2){ref-type="fig"}**, there were some chains performed consistently across different benchmark datasets. For instance, CUB-TIC-BAK and CUB-VSN-CEN performed superior in all datasets, while 2 other chains (NON-CYC-ZER and NON-MEA-SVD) performed poor in all seven benchmarks. It was of great interests to explore dataset-independent properties underlying the consistency across datasets, which thus inspired us to further investigate the similarity among performances of different analysis chains.

![Performances of 20 representative analysis chains across different datasets measured by PMAD values. The PMAD values within the ranges of ≤0.3, \>0.3 & ≤0.7, and \>0.7 was generally accepted as with superior, good, and poor performance, respectively ([@B13]; [@B69]), which was illustrated by the circles of different diameters (the smaller circle diameter indicated the lower PMAD value).](fphar-09-00681-g002){#F2}

Since the type of instrument (TripleTOF 5600 and 6600) covered by seven benchmark datasets were the same as that of 85 SWATH-MS based projects, those datasets could be recognized as representative datasets of SWATH-MS based pharmacoproteomic data. Thus, the discovery of analysis chain performed consistently well across the various datasets might give great insights into the selection of the most appropriate analysis chain in SWATH-MS based proteomic study. To identify such chains performed consistently well across datasets, the hierarchical clustering with the ward algorithm ([@B6]; [@B95]; [@B21]; [@B80]) was used to identify the "consistently well-performed" analysis chains (CWPACs) based on their PMAD values across different datasets. Theoretically, there were 560 possible analysis chains by randomly integrating 5 transformation, 16 normalization, and 7 imputation algorithms (including non-transformation, non-normalization, and non-imputation). 51 (9.1%) out of these 560 were with at least one PMAD value of the seven datasets unavailable due to the calculation error. Then, the PMAD values of the remaining 509 analysis chains were applied for clustering analysis. As illustrated in **Figure [3](#F3){ref-type="fig"}**, six partitions of the analysis chains (A~1~, A~2~, A~3~, B, C, and D) were identified. The PMADs meeting the "well-performed" criterion (≤0.7) were displayed by blue color, with the log ~10~PMAD ≤-5 set as exact blue and the larger log ~10~PMAD gradually fading toward white (PMAD = 0.7). Meanwhile, those "poor-performed" PMADs (\>0.7) were colored by orange, with log ~10~PMAD ≥ 5 set as exact orange and the smaller PMAD gradually fading toward white (PMAD = 0.7).

![Six partitions of analysis chains (A~1~, A~2~, A~3~, B, C, and D) were identified based on their PMAD values. PMAD values meeting the "well-performed" criterion (≤0.7) were displayed in blue color, with the log ~10~PMAD ≤-5 set as exact blue and the larger PMADs gradually fading toward white (PMAD = 0.7). Meanwhile, the "poor-performed" PMAD values (\>0.7) were all colored in orange, with log ~10~PMAD ≥ 5 set as exact orange and the smaller PMAD gradually fading toward white. The pink triangles indicated the analysis chains adopted by previous published SWATH-MS based proteomic studies.](fphar-09-00681-g003){#F3}

The analysis chains in the partition A~1~, A~2~, and A~3~ were "consistently well-performed" across all datasets (**Figure [3](#F3){ref-type="fig"}**). For partition A~1~, 320 (99.4%) out of 322 PMAD values were ≤0.1, and the remaining PMADs were ≤0.7 (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). For partition A~2~, 288 (52.7%), 209 (38.3%), and 40 (7.3%) out of those 546 PMAD values were ≤0.1, ≤0.3, and ≤0.7, respectively (Supplementary Figure [S2](#SM1){ref-type="supplementary-material"}). In partition A~3~, 187 (46.1%) and 183 (45.1%) out of 406 PMADs were ≤0.3 and ≤0.7, respectively (Supplementary Figure [S3](#SM1){ref-type="supplementary-material"}). In summary, 608 (47.7%), 396 (31.1%), and 225 (17.7%) out of all 1,274 PMADs in the partition combined by A~1~, A~2~, and A~3~ were ≤0.1, ≤0.3, and ≤0.7, respectively, indicating an extremely high percentage (96.5%) of the PMAD values meeting the widely adopted cutoff (PMAD = 0.7) for differentiating the chain of good and poor performances ([@B13]; [@B69]). Comprehensive literature review on the 85 SWATH-MS based proteomic projects further identified the analysis chains adopted by their corresponding studies (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). In total, there were 55 analysis chains previously applied in proteomic studies, which were mapped to and labeled on **Figure [3](#F3){ref-type="fig"}** (pink triangles). As illustrated, 7 (12.7%), 9 (16.4%), and 21 (38.2%) out of the 55 analysis chains previously adopted were within the partition A~1~, A~2~, and A~3~, respectively, which indicated that the majority (67.3%) of these analysis chains were the CWPACs.

As shown in Supplementary Figure [S4](#SM1){ref-type="supplementary-material"}, the percentage of each processing method adopted by the previous proteomic studies were analyzed. *[Log Transformation]{.ul}* was the only transformation method used in SWATH-MS based proteomic studies, and was widely recognized as powerful in quantifying thousands of proteins ([@B55]; [@B18]; [@B76]; [@B94]; [@B20]). For normalizations, *[Median Normalization]{.ul}, [Total Ion Current]{.ul}*, and *[Quantile Normalization]{.ul}* were the top-3 ranked methods in their popularity. The *Median* and *Quantile Normalization* were frequently adopted in MS-based label-free proteomic analyses ([@B10]), while the *Total Ion Current* was reported to be preferably used in the proteomic profiling based on MALDI- and SELDI-TOF mass spectra ([@B8]). For imputation, *[K-nearest Neighbor]{.ul}* and *[Background Imputation]{.ul}* accounted for \>80% of the SWATH-MS based proteomic studies adopting imputation methods. Among those methods used in proteomic studies (4 transformation, 15 normalization, and 6 missing-value imputation), Supplementary Figure [S4](#SM1){ref-type="supplementary-material"} showed that some methods were adopted seldomly in SWATH-MS based proteomic studies (such as *Box-Cox Transformation, Pareto Scaling*, and *Singular Value Decomposition*). Therefore, it is of great interests to discover whether there are other methods suitable or demonstrating enhanced performance in SWATH-MS based proteomic analysis.

Fifty-three analysis chains consistently performed poor among datasets were also discovered by **Figure [3](#F3){ref-type="fig"}** (partition D), all of which did not adopt any transformation method in their analysis. In total, 101 out of the 509 analysis chains (**Figure [3](#F3){ref-type="fig"}**) adopted non-transformation, and 53 (52.5%), 10 (9.9%), 11 (10.9%), 14 (13.9%), 6 (5.9%), and 7 (6.9%) out of these 101 chains were within the partition D, C, B, A~3~, A~2~, and A~1~, respectively. These results demonstrated the important roles played by transformation methods in the quantification performance of analysis chains.

Contribution of Each Processing Method to the Performance of Analysis Chain
---------------------------------------------------------------------------

With the discovery of a variety of CWPACs based on those independent benchmark datasets, it was interesting to go back to each processing method used to integrate these CWPACs, which might be able to discover processing methods with significant contributions to the performance of CWPACs. Therefore, all CWPACs listed in Supplementary Figures [S1](#SM1){ref-type="supplementary-material"}--[S3](#SM1){ref-type="supplementary-material"} were investigated by analyzing their corresponding processing methods. As shown in **Figure [4](#F4){ref-type="fig"}**, the percentage of each method appeared in 3 different partitions (A~1~ & A~2~ & A~3~, A~1~ & A~2~, and A~1~) were analyzed. For transformation, the percentage of *[Power Transformation]{.ul}* significantly increased from 7% to 10% to 29% with the gradual narrow down of partitions (from A~1~ & A~2~ & A~3~ to A~1~ & A~2~ to A~1~), which showed significantly enhanced role played by this transformation to achieve good performance in protein quantifications. However, *[Log Transformation]{.ul}* decreased greatly from 41% to 25% to 26%. This indicated that *Log Transformation* contributed most to the CWPACs compared to other transformations. But when it came to the superior performance (partition A~1~ with PMAD ≤ 0.1), its contribution decreased and ranked as the second. For normalization, the *[Total Ion Current]{.ul}* method stood out among all methods as the one with the highest contribution to CWPAC. With gradual narrow down of partitions (from A~1~ & A~2~ & A~3~ to A~1~ & A~2~ to A~1~), the importance of *Total Ion Current* method was enhanced significantly from 19% to 27% to 74%. For imputation, methods were almost evenly distributed with no clear change among different partitions. This indicated that each imputation method contributed equally to CWPACs, and the selection of any of those methods could not make statistical difference in protein quantification. Due to the equal contribution of imputation methods, it was essential to focus on selecting the appropriate combinations of transformation and normalization methods to achieve the optimal performance of analysis chains, which included POW-TMM, LOG-TIC, BOX-TIC, CUB-TIC, NON-TIC, POW-TIC, and LOG-VSN (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

![Percentages of each processing method (transformation, normalization, and imputation) appeared in three different partitions (A~1~ & A~2~ & A~3~, A~1~ & A~2~, and A~1~) shown in **Figure [3](#F3){ref-type="fig"}**. Each processing method was abbreviated by a three-letter code as demonstrated in Supplementary Table [S1](#SM1){ref-type="supplementary-material"}.](fphar-09-00681-g004){#F4}

Conclusion
==========

Based on the most complete set of the publicly available pharmacoproteomic data generated by SWATH-MS technique, this study revealed a substantial variation among the performances of various analysis chains applied for pharmacoproteomic quantification, and the analysis chains performed consistently well across a diverse set of publicly available pharmacoproteomic data were discovered. As a result, log and power transformations sequentially followed by total ion current normalization were discovered as one of the best performed analysis chains applied for the SWATH-MS based pharmacoproteomic quantification. In summary, the identified analysis chains provided important guidance to current proteomic research and could thus facilitate the cutting-edge research in any proteomic studies requiring SWATH-MS technique.
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